{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T09:44:30Z","timestamp":1753868670236,"version":"3.41.2"},"reference-count":40,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T00:00:00Z","timestamp":1603670400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Adjuvant carboplatin reduces relapse risk in clinical stage 1 (CS1) seminoma, though there is a paucity of long\u2010term safety data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>Our objective was to report long\u2010term outcomes of two cycles of adjuvant carboplatin dosed at area under the time\u2013concentration curve (AUC) of 7.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and results<\/jats:title><jats:p>We performed a retrospective analysis on treatment and outcomes of patients with CS1 seminoma who received adjuvant carboplatin from 2000 to 2016 at our centres in the Midland Region, New Zealand. Of 159 patients, median age 39\u2009years, 153 received two\u2009cycles of carboplatin: 147 dosed at AUC7 and 6 at AUC6. Six patients had one cycle of carboplatin AUC7. One patient relapsed at 22\u2009months and died of bleomycin pneumonitis 2 months after achieving a complete response with BEP chemotherapy. Neither RTI (present in 21.3%) nor tumor size &gt;4 cm (in 43.3%) was predictive of relapse. Median follow\u2010up was 106\u2009months. At 15\u2009years, outcomes were: relapse\u2010free survival 99.4%, overall survival 91.4%, disease\u2010specific survival 100%, subsequent malignant neoplasm rate 7.6%, and second testicular germ cell tumor rate 3.85%. One patient had persistent grade 1 thrombocytopenia at 46\u2009months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These data add to the body of evidence that two cycles of carboplatin AUC7 is safe and effective adjuvant treatment for CS1 seminoma.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cnr2.1310","type":"journal-article","created":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T12:33:52Z","timestamp":1603715632000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Two cycles of adjuvant carboplatin for clinical stage 1 testicular seminoma in New Zealand centres: A retrospective analysis of efficacy and long\u2010term events"],"prefix":"10.1002","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0150-7765","authenticated-orcid":false,"given":"Elias A.","family":"Chandran","sequence":"first","affiliation":[{"name":"Department of Oncology Waikato Hospital  Hamilton New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Chindewere","sequence":"additional","affiliation":[{"name":"Department of Oncology Waikato Hospital  Hamilton New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"North","sequence":"additional","affiliation":[{"name":"Department of Oncology Tauranga Hospital  Tauranga New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7068-4311","authenticated-orcid":false,"given":"Michael B.","family":"Jameson","sequence":"additional","affiliation":[{"name":"Department of Oncology Waikato Hospital  Hamilton New Zealand"},{"name":"Waikato Clinical Campus University of Auckland  Hamilton New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,10,26]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2015.04.003"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00991-5"},{"key":"e_1_2_11_4_1","unstructured":"Health. Mo. New cancer registrations.2017.Wellington New Zealand: Ministry of Health; 2019."},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.4531"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-019-02965-5"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2015.04.005"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.1044"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2011.03.008"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.4655"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.1.101"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm540"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.07.001"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.06.006"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.0958"},{"volume-title":"Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2","year":"2006","author":"Council NR","key":"e_1_2_11_16_1"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.061"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/pon.1437"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu437"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw164"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1159\/000487438"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2017.12.001"},{"key":"e_1_2_11_23_1","unstructured":"LagunaMP AlbersP AlgabaF et al.EAU guidelines on testicular cancer 2020. In: European Association of Urology Guidelines 2020 Edition. Vol. Presented at the EAU Annual Congress Amsterdam 2020. Arnhem The Netherlands: European Association of Urology Guidelines Office;2020."},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.06.047"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.09.025"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf058"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv369"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.4174"},{"key":"e_1_2_11_29_1","unstructured":"Boards MDH.Regional Services Plan 2018\u20132021: Strategic Direction. [Internet]. Hamilton: HealthShare Ltd for the Midland DHBs; 2018 [cited July 22 2020]. Available from:https:\/\/healthshare.health.nz\/sites\/default\/files\/images\/2018-2021%20Midland%20Regional%20Services%20Plan%20-%20Strategic%20Direction.pdf"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.0503"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09658.x"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-9056(09)75073-0"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.9810"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg241"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1159\/000474497"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2015.12.009"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-016-2162-z"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.09.028"},{"key":"e_1_2_11_39_1","first-page":"780","article-title":"Fifteen\u2010year follow\u2010up of the anglian germ cell cancer group adjuvant studies of carboplatin as an alternative to radiation or surveillance for stage 1 seminoma","volume":"19","author":"Oliver R","year":"2001","journal-title":"Proc ASCO"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)00376-3"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(94)90219-4"}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.1310","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cnr2.1310","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.1310","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T07:26:02Z","timestamp":1693553162000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.1310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,26]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1002\/cnr2.1310"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.1310","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"type":"print","value":"2573-8348"},{"type":"electronic","value":"2573-8348"}],"subject":[],"published":{"date-parts":[[2020,10,26]]},"assertion":[{"value":"2020-07-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1310"}}